Key clinical point: In patients with chronic-phase chronic myeloid leukemia (CML-CP) undergoing tyrosine kinase inhibitor (TKI) treatment, the European Treatment and Outcome Study for CML long-term survival (ELTS) offered better overall prediction accuracy than the Sokal score, especially in those receiving the second-generation TKI (2G-TKIs).
Major finding: Overall, ELTS was a better predictor of molecular response (MR)4 (high vs. low; hazard ratio [HR], 0.6; P = .013), MR4.5 (high vs. low; HR, 0.6; P = .030), and CML-related survival ( high vs. low; HR, 4.3; P < .001 ) than the Sokal score. In patients receiving 2G-TKIs, only the ELTS score predicted complete cytogenic response, major MR, MR4, and failure- and progression-free survival (all P < .05).
Study details: Findings are from a retrospective analysis of 1,661 adult patients with newly
diagnosed CML-CP receiving either imatinib, dasatinib, or nilotinib.
Disclosures: This study was partly funded by the National Nature Science Foundation of China. RP
Gale reported ties with various pharmaceutical companies. Other authors had no disclosures.
Source: Zhang XS et al. Leukemia. 2021 Aug 19. doi: 10.1038/s41375-021-01387-y .